These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23228934)

  • 41. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of eastern Nepal.
    Shrestha S; Amatya R; Dutta R
    Nepal Med Coll J; 2011 Sep; 13(3):186-9. PubMed ID: 22808812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
    Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
    Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Faecal carriage of carbapenemase-producing Gram-negative bacilli in hospital settings in southern France.
    Pantel A; Marchandin H; Prère MF; Boutet-Dubois A; Brieu-Roche N; Gaschet A; Davin-Regli A; Sotto A; Lavigne JP
    Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):899-904. PubMed ID: 25532506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA; Dzierzanowska D; Turner PJ
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of a hospital-wide antimicrobial formulary intervention on the incidence of multidrug-resistant gram-negative bacteria.
    Furtado GH; Perdiz LB; Santana IL; Camargo MM; Parreira FC; Angelieri DB; Medeiros EA
    Am J Infect Control; 2008 Nov; 36(9):661-4. PubMed ID: 18834728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp.
    Lee K; Ha GY; Shin BM; Kim JJ; Kang JO; Jang SJ; Yong D; Chong Y;
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):51-8. PubMed ID: 15380278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit.
    Nseir S; Blazejewski C; Lubret R; Wallet F; Courcol R; Durocher A
    Clin Microbiol Infect; 2011 Aug; 17(8):1201-8. PubMed ID: 21054665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance patterns among selective Gram-negative bacilli from an intensive care unit in Trinidad, West Indies.
    Orrett FA
    Saudi Med J; 2004 Apr; 25(4):478-83. PubMed ID: 15083220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers.
    Marchiaro P; Ballerini V; Spalding T; Cera G; Mussi MA; Morán-Barrio J; Vila AJ; Viale AM; Limansky AS
    J Antimicrob Chemother; 2008 Aug; 62(2):336-44. PubMed ID: 18456651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.
    Hirsch EB; Guo B; Chang KT; Cao H; Ledesma KR; Singh M; Tam VH
    J Infect Dis; 2013 Mar; 207(5):786-93. PubMed ID: 23242537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
    Streit JM; Jones RN; Sader HS; Fritsche TR
    Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
    Maltezou HC
    Int J Antimicrob Agents; 2009 May; 33(5):405.e1-7. PubMed ID: 19095416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.